Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

6.1K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.1K
Mitochondria01:37

Mitochondria

21.1K
Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
21.1K
Aging01:26

Aging

945
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
945

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unraveling the intersection of aging and Parkinson's disease: a collaborative roadmap for advancing research models.

NPJ Parkinson's disease·2026
Same author

Circulating monocytes expressing senescence-associated features are enriched in COVID-19 patients with severe disease.

Aging cell·2023
Same author

Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD): A Pilot Clinical Trial.

The journal of prevention of Alzheimer's disease·2022
Same author

Senolytic drugs: from discovery to translation.

Journal of internal medicine·2020
Same author

The evolving microenvironment of the human hepatocyte: Healthy vs. cirrhotic liver vs. isolated cells.

Tissue & cell·2020
Same author

Proceedings of the Canadian Frailty Network Workshop: Identifying Biomarkers of Frailty to Support Frailty Risk Assessment, Diagnosis and Prognosis. Toronto, January 15, 2018.

The Journal of frailty & aging·2019

Related Experiment Video

Updated: Mar 13, 2026

Techniques to Induce and Quantify Cellular Senescence
06:51

Techniques to Induce and Quantify Cellular Senescence

Published on: May 1, 2017

35.4K

Molecular pathology endpoints useful for aging studies.

L J Niedernhofer1, J L Kirkland2, W Ladiges3

  • 1Department of Metabolism and Aging, The Scripps Research Institute, Jupiter, FL 33458, United States.

Ageing Research Reviews
|October 11, 2016
PubMed
Summary
This summary is machine-generated.

The Targeting Aging with Metformin (TAME) trial is launching soon. This review addresses the critical need for validated surrogate markers to measure aging and healthspan in future clinical trials.

Keywords:
Aging endpointsBiological ageGeropathologyMolecular pathologySurrogate markers of agingTranslational biomarkers of aging

More Related Videos

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

8.9K
SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
07:39

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

25.4K

Related Experiment Videos

Last Updated: Mar 13, 2026

Techniques to Induce and Quantify Cellular Senescence
06:51

Techniques to Induce and Quantify Cellular Senescence

Published on: May 1, 2017

35.4K
A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

8.9K
SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
07:39

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

25.4K

Area of Science:

  • Gerontology and clinical trial design.
  • Biomarker discovery for aging processes.

Background:

  • The upcoming Targeting Aging with Metformin (TAME) trial marks a new era in aging research.
  • Numerous interventions show promise in preclinical models, but clinical translation faces challenges.
  • The TAME trial benefits from extensive metformin data, simplifying endpoint selection.

Purpose of the Study:

  • To address the challenge of selecting appropriate endpoints for aging clinical trials, especially for novel therapeutics.
  • To identify and analyze molecular endpoints currently used as indicators of age-related conditions.
  • To propose a framework for validating and prioritizing these surrogate markers.

Main Methods:

  • Comprehensive review of existing molecular endpoints used in aging research.
  • Analysis of endpoints as indices for morbidity, frailty, and mortality.
  • Development of a strategic approach for endpoint validation and prioritization.

Main Results:

  • Identification of a wide range of molecular markers currently employed in aging studies.
  • Highlighting the need for standardized and validated surrogate markers for efficient clinical trials.
  • The review provides a foundation for selecting robust endpoints for future aging interventions.

Conclusions:

  • Validated surrogate markers are essential for the economic and timely progression of aging clinical trials.
  • A systematic approach to endpoint validation is crucial for advancing therapeutic interventions targeting aging.
  • This work aims to facilitate the development and success of future clinical trials in aging research.